drugset
drugset / Trial / NCT06263491

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

NCT06263491 ↗

Phase 2 Recruiting 50 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn if the chemotherapy-free combination of pirtobrutinib (also called LOXO-305) and rituximab can help provide long term remission in low and intermediate risk MCL.

Timeline

Start
2024-05-29
Primary completion
2026-11-01
Completion
2027-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirtobrutinib Other / unclassified — Oral
Subject Rituximab Monoclonal antibody — Oral

Indications

mantle cell lymphoma